ATEC Options (ATEC20260220P17.5) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About ATEC20260220P17.5

Underlying

Alphatec Holdings, Inc.

Industry

Healthcare Equipment and Supplies

Introduction

Alphatec Holdings, Inc., was incorporated in Delaware in March 2005. The company is a medical technology company that designs, develops, manufactures and sells surgical treatment products for spinal diseases, focusing on the treatment of factors affecting spinal aging. The company has a comprehensive product portfolio and pipeline that addresses the cervical and thoracic intervertebral areas, covering a variety of spinal diseases. The company's main products focus on the global orthopedic spine disease solutions market. The company's "surgical culture" emphasizes collaborating with spinal surgeons to design and co-develop a range of products. The company has advanced production equipment, unique competitive advantages and enables it to quickly provide solutions to meet the acute needs of doctors and patients. The company's products and systems, functional enhancements, products can appeal to surgeons, a combination of products and systems can provide a comprehensive solution for the safe and successful surgical treatment of spinal diseases. All implants sold by the company in the United States are approved by the U.S. Food and Drug Administration. The company's strategic goal is to become the world's leading independent full-line spine company with a focus on solutions for spinal aging. The aging spine has its own unique characteristics, and its solution is for patients with osteoporosis, vertebral compression fractures, scoliosis or deformity, degenerative disc disease, and spinal stenosis. To further differentiate its solutions, the company has fused minimally invasive technology and biologics into the company's product portfolio to improve patient outcomes.